ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
drugs
December 29, 2018For adults with type 2 diabetes initiating second-line antidiabetic medications (ADM), cardiovascular risk is increased with use of sulfonylureas or basal insulin versus newer ADM classes..... -
Novartis invests in Ionis’ therapies to reduce cardiovascular risk
europeanpharmaceuticalreview
January 11, 2017Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels o
Pharma Sources Insight January 2025
